- ISIN
- IL0010852080
- CUSIP
- M25722105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Aug 11, 2000
Highlights
- Market Cap
- $195.73M
- Enterprise Value
- $186.79M
- EPS (TTM)
- $0.37
- PE Ratio
- 5.59
- Total Revenue (TTM)
- $72.66M
- Gross Profit (TTM)
- $63.98M
- EBITDA (TTM)
- $32.73M
- Year Range
- $1.30 - $3.24
- Target Price
- $4.00
- ROA (TTM)
- 23.90%
- ROE (TTM)
- 36.55%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CGEN Performance Chart
Compugen Ltd. (CGEN) is up 35.3% since the beginning of the year. At $2 per share, CGEN is trading 36.0% below its 52-week high of $3. Investors who bought $1,000 worth of CGEN shares 5 years ago would now be looking at an investment worth $266.
Loading charts...
Returns By Period
Compugen Ltd. (CGEN) has returned 35.29% so far this year and 26.22% over the past 12 months. Over the last ten years, CGEN has returned -11.06% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Compugen Ltd.
- 1D
- 2.99%
- 1M
- -26.07%
- YTD
- 35.29%
- 6M
- 35.29%
- 1Y
- 26.22%
- 3Y*
- 27.02%
- 5Y*
- -23.26%
- 10Y*
- -11.06%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
CGEN Monthly Returns History
Based on dividend-adjusted daily data since Aug 11, 2000, CGEN's average daily return is +0.09%, while the average monthly return is +1.87%. At this rate, an investment would double in approximately 3.1 years.
Historically, 45% of months were positive and 55% were negative. The best month was Dec 2023 with a return of +198.8%, while the worst month was Nov 2008 at -58.9%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 9 months.
On a daily basis, CGEN closed higher 45% of trading days. The best single day was Dec 19, 2023 with a return of +174.0%, while the worst single day was Nov 5, 2008 at -30.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 20.26% | -1.63% | 17.68% | 24.88% | -1.13% | -21.29% | 35.29% | ||||||
| 2025 | 52.29% | -17.60% | -23.96% | 9.59% | -8.13% | 21.09% | -18.54% | -2.76% | 4.26% | 20.41% | -11.86% | -1.92% | -0.00% |
| 2024 | 21.72% | 7.05% | -0.00% | -25.19% | 12.44% | -22.58% | 5.36% | 18.64% | -13.81% | -11.60% | -0.62% | -3.77% | -22.73% |
| 2023 | 21.39% | -9.05% | -11.16% | -15.95% | 72.88% | 11.76% | 1.75% | -1.72% | -18.42% | -18.28% | -12.80% | 198.78% | 176.65% |
| 2022 | -17.44% | -12.96% | 4.21% | -26.09% | -22.27% | 0.00% | -12.97% | -27.33% | -43.85% | 44.87% | 26.08% | -40.36% | -83.36% |
| 2021 | 0.41% | -23.27% | -7.93% | 0.47% | -11.01% | 7.81% | -18.00% | 3.39% | -14.96% | 8.71% | -31.90% | -2.71% | -64.49% |
Benchmark Metrics
Compugen Ltd. has an annualized alpha of 15.10%, beta of 0.96, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since August 11, 2000.
- This stock participated in 178.58% of S&P 500 Index downside but only 161.16% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 15.10%
- Beta
- 0.96
- R²
- 0.05
- Upside Capture
- 161.16%
- Downside Capture
- 178.58%
Return for Risk
Risk / Return Rank
CGEN ranks 57 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Compugen Ltd. (CGEN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CGEN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.65 | ||
| Sortino ratioReturn per unit of downside risk | -1.59 | ||
| Omega ratioGain probability vs. loss probability | 1.13 | 1.37 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | 0.72 | 2.78 | -2.07 |
| Martin ratioReturn relative to average drawdown | 1.29 | 12.44 | -11.14 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Compugen Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Compugen Ltd. was 97.90%, occurring on Nov 24, 2008. Recovery took 2953 trading sessions.
The current Compugen Ltd. drawdown is 89.36%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Financial crisis2007–2009 | -97.90%Nov 2008 | 8y 2mo | 11y 9mo | 19y 11moSep 2000 - Aug 2020 |
2023 bear market2023 | -97.28%Nov 2023 | 3y 2mo | — | 5y 10moAug 2020 - now |
Dot-com crash2000–2002 | -15.01%Aug 2000 | 1d | 6d | 7dAug 2000 - Aug 2000 |
2020 pullback2020 | -2.06%Aug 2020 | 0s | 5d | 5dAug 2020 - Aug 2020 |
Dot-com crash2000–2002 | -0.96%Aug 2000 | 0s | 1d | 1dAug 2000 - Aug 2000 |
Drawdown Indicators
| CGEN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.90% | -56.78% | -41.12% |
Max Drawdown (1Y)Largest decline over 1 year | -36.77% | -9.10% | -27.67% |
Max Drawdown (3Y)Largest decline over 3 years | -60.00% | -18.90% | -41.10% |
Max Drawdown (5Y)Largest decline over 5 years | -94.00% | -25.43% | -68.57% |
Max Drawdown (10Y)Largest decline over 10 years | -97.28% | -33.92% | -63.36% |
Current DrawdownCurrent decline from peak | -89.36% | -1.80% | -87.56% |
Average DrawdownAverage peak-to-trough decline | -75.80% | -10.71% | -65.09% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.31% | 2.03% | +18.28% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Compugen Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Compugen Ltd. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for CGEN, comparing it with other companies in the Biotechnology industry. Currently, CGEN has a P/E ratio of 5.6. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CGEN relative to other companies in the Biotechnology industry. Currently, CGEN has a P/S ratio of 2.7. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CGEN in comparison with other companies in the Biotechnology industry. Currently, CGEN has a P/B value of 2.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CGEN
Add Compugen Ltd. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CGEN